The U.S. Food and Drug Administration (FDA) announced Wednesday that it will relax certain rules for approving low-cost versions of some high-priced medications, in an effort to speed up access to ...
But last week, those words took on the force of law. On Tuesday, Texas Attorney General Ken Paxton filed a lawsuit against ...
The U.S. Food and Drug Administration announced it will relax certain rules for approving low-cost versions of some high-priced medications to reduce costs.
The FDA’s new draft guidance aims to make the approval process faster and less burdensome by limiting the need for ...
Once those prices are set, most large government programs that cover prescription drugs pay prices that are tied to ...
The draft guidance, which is touted as a way to reduce the cost and time-associated burden of biosimilar development, has ...
Q1 2026 Earnings Call October 29, 2025 8:01 PM EDTCompany ParticipantsGregory Brown - CEO, MD & DirectorArun Singh ...
The U.S. Food and Drug Administration will take steps to streamline the process to develop generic versions of complex ...
The Food and Drug Administration (FDA) is launching an effort to streamline the approval process for cheaper alternative ...
The agency announced moves to cut regulatory obstacles for the makers of biosimilar drugs, which are akin to generics and may ...
AI and accelerated computing are transforming the bio/pharmaceutical sector by addressing organizational, technological, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback